EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Ushering in the era of tRNA medicines

Theonie Anastassiadis, Caroline Köhrer

Journal of Biological Chemistry · 2023-10 · 299 (10) · 105246

DOI: 10.1016/j.jbc.2023.105246 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Biological Chemistry, 2023-10. Verfasst von Theonie Anastassiadis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Alltrna, Inc, Cambridge, Massachusetts, USA. Electronic address: Theonie@alltrna.com. Hauptthemen laut MEDLINE: RNA, Transfer. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long viewed as an intermediary in protein translation, there is a growing awareness that tRNAs are capable of myriad other biological functions linked to human health and disease. These emerging roles could be tapped to leverage tRNAs as diagnostic biomarkers, therapeutic targets, or even as novel medicines. Furthermore, the growing array of tRNA-derived fragments, which modulate an increasingly broad spectrum of cellular pathways, is expanding this opportunity. Together, these molecules offer drug developers the chance to modulate the impact of mutations and to alter cell homeostasis. Moreover, because a single therapeutic tRNA can facilitate readthrough of a genetic mutation shared across multiple genes, such medicines afford the opportunity to define patient populations not based on their clinical presentation or mutated gene but rather on the mutation itself. This approach could potentially transform the treatment of patients with rare and ultrarare diseases. In this review, we explore the diverse biology of tRNA and its fragments, examining the past and present challenges to provide a comprehensive understanding of the molecules and their therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, TransferHumansAnimalsMutationProtein Biosynthesis

Stichwörter der Autor:innen

RNA modificationdrug designgenetic diseasemachine learningprogrammable RNAtRNAtRNA fragmentstRNA medicinestRNA therapeuticstranscriptiontranslation

Substanzen

RNA, Transfer

Autor:innen und Institutionen

  • Alltrna, Inc, Cambridge, Massachusetts, USA. Electronic address: Theonie@alltrna.com.
  • Alltrna, Inc, Cambridge, Massachusetts, USA.

Zitieren

APA

Anastassiadis, T., & Köhrer, C. (2023). Ushering in the era of tRNA medicines. Journal of Biological Chemistry, 299(10), 105246. https://doi.org/10.1016/j.jbc.2023.105246

Vancouver

Anastassiadis T, Köhrer C. Ushering in the era of tRNA medicines. Journal of Biological Chemistry. 2023;299(10):105246. doi:10.1016/j.jbc.2023.105246

BibTeX
@article{Anastassiadis2023,
  author = {Anastassiadis, Theonie and Köhrer, Caroline},
  title = {Ushering in the era of tRNA medicines},
  journal = {Journal of Biological Chemistry},
  year = {2023},
  volume = {299},
  number = {10},
  pages = {105246},
  doi = {10.1016/j.jbc.2023.105246}
}
Kostenlos starten →